Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial In Schizophrenia

Concert Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for schizophrenia. CTP-692 is a deuterated form of D-serine, an endogenous amino acid that is a co-agonist of the NMDA receptor. NMDA is believed to play a key role in schizophrenia. The Phase 2 trial is designed to evaluate the safety and efficacy of three different doses of CTP-692, compared with placebo, in individuals with schizophrenia who are stable on an antipsychotic medication. The company expects to report topline Phase 2 data by year end 2020.

The . . .